![logo](/logos/CYTH.webp)
Cyclo Therapeutics, Inc.
NASDAQ:CYTH
0.68 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Cyclo Therapeutics, Inc. |
Symbool | CYTH |
Munteenheid | USD |
Prijs | 0.68 |
Beurswaarde | 19,513,280 |
Dividendpercentage | 0% |
52-weken bereik | 0.65 - 2.12 |
Industrie | Drug Manufacturers—Specialty & Generic |
Sector | Healthcare |
CEO | Mr. N. Scott Fine |
Website | https://www.cyclotherapeutics.com |
An error occurred while fetching data.
Over Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)